{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.84","upperLimit":"90.57","value":"33.3"},{"groupId":"OG001","lowerLimit":"22.28","upperLimit":"95.67","value":"66.7"},{"groupId":"OG002","lowerLimit":"11.81","upperLimit":"88.19","value":"50.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants who achieved a confirmed PR or better during the study in the safety population. ORR will be assessed by the investigator per IMWG criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received modakafusp alfa 80 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 60 weeks.","id":"OG000","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 80 mg + Daratumumab"},{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 48 weeks.","id":"OG001","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 120 mg + Daratumumab"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 36 weeks.","id":"OG002","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 240 mg + Daratumumab"}],"paramType":"NUMBER","populationDescription":"The Response-evaluable Population included all participants who received at least 1 dose, even an incomplete dose, of any study drug, have a disease assessment at screening (baseline evaluation), and at least 1 postbaseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Phase 1: Up to 15.9 months","title":"Phase 1: Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}